P27Kip1 V109G polymorphism and cancer risk: A systematic review and meta-analysis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 10, 2012, Pages 665-671

  Wei, Feng ^a   Xu, Jin ^a   Tang, Lin ^a   Shao, Jiaqing ^a   Wang, Yucai ^a   Chen, Longbang ^a   Guan, Xiaoxiang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

cancer; p27; polymorphism; risk; V109G

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ALLELE; ASIAN; BREAST CANCER; CANADA; CANCER RISK; EUROPEAN AMERICAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84870832862     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1229     Document Type: Review

References (30)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The nextgeneration. Cell 2011;144:646.
2. Payton M, Chung G, Yakowec P, et al. Discovery andevaluation of dual CDK1 and CDK2 inhibitors. Cancer Res2006;66:4299.
3. Starostina NG, Kipreos ET. Multiple degradation pathwaysregulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol2012;22:33.
4. Kumar PS, Shiras A, Das G, et al. Differential expression androle of p21cip/waf1 and p27 in TNF-alpha-induced inhibition ofproliferation in human glioma cells. Mol Cancer 2007;6:42.
5. Fearon E. The sweet secrets of p27 regulation and function incell migration. Cell Cycel 2011;10:3429.
6. Itamochi H, Yoshida T, Walker CL, et al. Novel mechanismof reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol2011;122:641.
7. Molatore S, Marinoni I, Lee M, et al. A novel germlineCDKN1B mutation causing multiple endocrine tumors:Clinical, genetic and functional characterization. Hum Mutat2010;31:E1825.
8. Molatore S, Kiermaier E, Jung CB, et al. Characterization of anaturally-occurring p27mutation predisposing to multipleendocrine tumors. Mol Cancer 2012;9:116.
9. Pasquali D, Circelli L, Faggiano A, et al. CDKN1BV109G polymorphism a new prognostic factor in sporadicmedullary thyroid carcinoma. Eur J Endocrinol 2011;164:397.
10. Tomoda K, Kubota Y, Kato J. Degradation of the cyclindependent-kinase inhibitor p27 is instigated by Jab1. Nature1999;398:160.
11. Teng EC, Todd LR, Ribar TJ, et al. Gfer inhibits Jab1-mediated degradation of p27 to restrict proliferation ofhematopoietic stem cells. Mol Biol Cell 2011;22:1312.
12. Li G, Sturgis EM, Wang LE, et al. Association between theV109G polymorphism of the p27 gene and the risk andprogression of oral squamous cell carcinoma. Clin CancerRes 2004;10:3996.
13. Kibel AS, Suarez BK, Belani J, et al. CDKN1A and CDKN1Bpolymorphisms and risk of advanced prostate carcinoma.Cancer Res 2003;63:2033.
14. Figueiredo JC, Knight JA, Cho S, et al. PolymorphismscMyc-N11S and p27-V109G and breast cancer risk andprognosis. BMC Cancer 2007;7:99.
15. Naidu R, Har YC, Taib NA. P27 V109G Polymorphism isassociated with lymph node metastases but not with increasedrisk of breast cancer. J Exp Clin Cancer Res 2007;26:133.
16. Ma H, Jin G, Zhai X, et al. Variant genotypes of CDKN1Aand CDKN1B are associated with an increased risk ofbreast cancer in Chinese women. Int J Cancer 2006;119:2173.
17. Onay VU, Briollais L, Knight JA, et al. SNP-SNP interactionsin breast cancer susceptibility. BMC Cancer 2006;6:114.
18. Spurdle AB, Deans AJ, Duffy D, et al. No evidence thatCDKN1B (p27) polymorphisms modify breast cancer risk inBRCA1 and BRCA2 mutation carriers. Breast Cancer ResTreat 2009;115:307.
19. Chen J, Amos CI, Merriman KW, et al. Genetic variants ofp21 and p27 and pancreatic cancer risk in non-HispanicWhites: A case-control study. Pancreas 2010;39:1.
20. Chen J, Killary AM, Sen S, et al. Polymorphisms of p21 andp27 jointly contribute to an earlier age at diagnosis of pancreaticcancer. Cancer Lett 2008;272:32.
21. Huang SP, Yu CC, Liu CC, et al. CDKN1B V109G polymorphismfrequency and prostate cancer risk in Taiwan.Urol Int 2008;81:36.
22. Landa I, Montero-Conde C, Malanga D, et al. Allelic variantat-79 (C > T) in CDKN1B (p27) confers an increased risk ofthyroid cancer and alters mRNA levels. Endocr Relat Cancer2010;17:317.
23. Berry KJ, Johnston JE, Mielke PW, Jr. An alternative measureof effect size for Cochran's Q test for related proportions.Percept Mot Skills 2007;104:1236.
24. Grizzle JE. Analysis of data from multiclinic trials. ControlClin Trials 1987;8:392.
25. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysisdetected by a simple, graphical test. BMJ 1997;315:629.
26. Macaskill P, Walter SD, Irwig L. A comparison of methodsto detect publication bias in meta-analysis. Stat Med 2001;20:641.
27. Palma Perez S, Delgado Rodriguez M. Practical considerationson detection of publication bias. Gac Sanit 2006;20:10.
28. Guan X, Wang Y, Chen L, et al. p27(Kip1) as a prognosticfactor in breast cancer:a systematic review and metaanalysis.J Cell Mol Med 2010;14:944.
29. Hershko DD. Cyclin-dependent kinase inhibitor p27 as aprognostic biomarker and potential cancer therapeutic target.Future Oncol 2010;6:1837.
30. Wander SA, Zhao D, Slinqerland JM. p27: A Barometer ofsignaling deregulation and potential predictor of response totargeted therapies. Clin Cancer Res 2011;17:12.